- Full Year 2023 HUTCHMED (China) Ltd Earnings Call TranscriptFeb 28, 2024€2.9 (+5.07%)Earnings
- HUTCHMED (China) Ltd at Deutsche Bank ADR Investor Conference (Virtual) TranscriptNov 09, 2023
- Half Year 2023 HUTCHMED (China) Ltd Earnings Call TranscriptJul 31, 2023€2.52 (+1.61%)Earnings
- HUTCHMED (China) Ltd at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- HUTCHMED (China) Ltd at Jefferies Healthcare Conference TranscriptJun 08, 2023
- HUTCHMED (China) Ltd at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Full Year 2022 HUTCHMED (China) Ltd Earnings Call TranscriptFeb 28, 2023Earnings
- HUTCHMED (China) Ltd Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China Call TranscriptJan 23, 2023
- HUTCHMED (China) Ltd at OTC Markets and Deutsche Bank dbVIC ADR Virtual Investor Conference TranscriptNov 17, 2022
- HUTCHMED (China) Ltd at Bank of America Precision Oncology Conference TranscriptOct 03, 2022
- HUTCHMED (China) Ltd FRESCO-2 Data at ESMO Call TranscriptSep 12, 2022
- Half Year 2022 HUTCHMED (China) Ltd Earnings Call TranscriptAug 01, 2022€2.38 (+0.85%)Earnings
- HUTCHMED (China) Ltd Company Update: Surufatinib FDA NDA Status Corporate Call TranscriptMay 02, 2022
- Full Year 2021 HUTCHMED (China) Ltd Earnings Call TranscriptMar 03, 2022€4.28 (-6.14%)Earnings
- HUTCHMED (China) Ltd at OTC Markets and Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptNov 17, 2021
- HUTCHMED (China) Ltd and Epizyme Inc Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® in Greater China Call TranscriptAug 09, 2021
- Half Year 2021 HUTCHMED (China) Ltd Earnings Call TranscriptJul 28, 2021€6.65 (+7.26%)Earnings
- HUTCHMED (China) Ltd at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- HUTCHMED (China) Ltd Corporate Call TranscriptMay 27, 2021
- HUTCHMED (China) Ltd virtual investor update Call TranscriptMay 26, 2021
- HUTCHMED (China) Ltd at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 11, 2021
- Full Year 2020 Hutchison China MediTech Ltd Earnings Call TranscriptMar 04, 2021€4.58 (-3.78%)Earnings
- Hutchison China MediTech Ltd at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Half Year 2020 Hutchison China MediTech Ltd Earnings Call TranscriptJul 30, 2020€4.31 (+0.23%)Earnings
- Hutchison China MediTech Ltd Investor Update at ASCO TranscriptJun 01, 2020
- Hutchison China MediTech Ltd at Bank of America Merrill Lynch Healthcare Conference (Virtual) TranscriptMay 14, 2020
- Hutchison China MediTech Ltd at PR Newswire and BetterInvesting (NAIC) Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptMar 19, 2020
- Full Year 2019 Hutchison China MediTech Ltd Earnings Call TranscriptMar 03, 2020€4.06 (+3.05%)Earnings
- Hutchison China MediTech Ltd at JPMorgan Healthcare Conference TranscriptJan 15, 2020
- Hutchison China MediTech Ltd at Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptNov 13, 2019
- Hutchison China MediTech Limited - Special Call TranscriptSep 30, 2019
- Hutchison China MediTech Ltd at Morgan Stanley Healthcare Conference TranscriptSep 11, 2019
- Half Year 2019 Hutchison China MediTech Ltd Earnings Presentation TranscriptJul 30, 2019
- Hutchison China MediTech Ltd at Deutsche Bank Depositary Receipts Virtual Investor Conference TranscriptMay 15, 2019
- Full Year 2018 Hutchison China MediTech Ltd Earnings Call TranscriptMar 11, 2019Earnings
- Full Year 2018 Hutchison China MediTech Ltd Earnings Call TranscriptMar 11, 2019Earnings
Hutchison China MediTech Ltd at JPMorgan Healthcare Conference Transcript
Okay. Good afternoon, everyone. I'm David Li from JPMorgan Equity Research. Now it's my pleasure to introduce Mr. Hogg, the CEO of Hutchison China MediTech. Thank you.
Thank you, David. Okay. So we've got 25 minutes. I'm going to take everybody through a brief summary of our business and the current status and the outlook for the year. So on a high level, what is Hutchison China MediTech trying to achieve? We're obviously a China-based biotech that is endeavoring to become a global biotech. We have developed -- discovered and developed a range of small molecule targeted therapies, all of which have been designed for the global market. But obviously, with our location in China, and that being our home market, our first step is to maximize the potential in China. But we are very much focused on becoming a global based -- a global science-focused biotech based in China.
So looking at our operations, it sort of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)